Prostate Cancer Risk with Positive Family History, Normal Prostate Examination Findings, and PSA Less Than 4.0 ng/mL

Urology

Volumn 70, Issue 4, 2007, Pages 748-752

  Canby Hagino, Edith ^a,b   Hernandez, Javier ^b   Brand, Timothy C ^a   Troyer, Dean A ^a   Higgins, Betsy ^a   Ankerst, Donna Pauler ^a   Thompson, Ian M ^a   Leach, Robin J ^a   Parekh, Dipen J ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; DIGITAL RECTAL EXAMINATION; FAMILY HISTORY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; DIGITAL RECTAL EXAMINATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 35648951103     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.06.1105     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66-70
3. Kupelian P., Katcher J., Levin H., et al. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48 (1996) 249-260
4. Antenor J.A., Roehl K.A., Eggener S.E., et al. Preoperative PSA and progression-free survival after radical prostatectomy for stage T1c disease. Urology 66 (2005) 156-160
5. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. [Erratum appears in N Engl J Med 351: 1470, 2004]. N Engl J Med 350 (2004) 2239-2246
6. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343 (2000) 78-85
7. Page W.F., Braun M.M., Partin A.W., et al. Heredity and prostate cancer: a study of World War II veteran twins. Prostate 33 (1997) 240-245
8. Verkasalo P.K., Kaprio J., Koskenvuo M., et al. Genetic predisposition, environment and cancer incidence: a nationwide twin study in Finland, 1976-1995. Int J Cancer 83 (1999) 743-749
9. Karan D., Lin M.F., Johansson S.L., et al. Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer 103 (2003) 285-293
10. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 168 (2002) 906-913
11. Scott K.M., Fanta P., Calaluce R., et al. Diagnostic frozen prostate sextant biopsies: an approach for preserving protein and RNA for additional studies. Prostate 44 (2000) 296-302
12. Balic I., Graham S.T., Troyer D.A., et al. Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol 168 (2002) 2245-2248
13. Hernandez J., Balic I., Johnson-Pais T.L., et al. Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol 175 (2006) 523-527
14. Morganti G., Gianferrari L., Cresseri A., et al. [Clinico-statistical and genetic research on neoplasms of the prostate]. Acta Genet Stat Med 6 (1956) 304-305
15. Woolf C.M. An investigation of the familial aspects of carcinoma of the prostate. Cancer 13 (1960) 739-744
16. Bruner D.W., Moore D., Parlanti A., et al. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 107 (2003) 797-803
17. Johns L.E., and Houlston R.S. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 91 (2003) 789-794
18. Hayes R.B., Liff J.M., Pottern L.M., et al. Prostate cancer risk in U.S. blacks and whites with a family history of cancer. Int J Cancer 60 (1995) 361-364
19. Zeegers M.P., Jellema A., and Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 97 (2003) 1894-1903
20. Spitz M.R., Currier R.D., Fueger J.J., et al. Familial patterns of prostate cancer: a case-control analysis. J Urol 146 (1991) 1305-1307
21. Schuurman A.G., Zeegers M.P., Goldbohm R.A., et al. A case-cohort study on prostate cancer risk in relation to family history of prostate cancer. Epidemiology 10 (1999) 192-195
22. Cerhan J.R., Parker A.S., Putnam S.D., et al. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev 8 (1999) 53-60
23. Jacobsen P.B., Lamonde L.A., Honour M., et al. Relation of family history of prostate cancer to perceived vulnerability and screening behavior. Psycho-Oncology 13 (2004) 80-85
24. Bock C.H., Peyser P.A., Gruber S.B., et al. Prostate cancer early detection practices among men with a family history of disease. Urology 62 (2003) 470-475
25. Durham J., Low M., and McLeod D. Screening for prostate cancer: a survey of New Zealand general practitioners. N Z Med J 116 (2003) U476
26. Tudiver F., Guibert R., Haggerty J., et al. What influences family physicians' cancer screening decisions when practice guidelines are unclear or conflicting?. J Fam Pract 51 (2002) 760
27. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
28. Krumholtz J.S., Carvalhal G.F., Ramos C.G., et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 60 (2002) 469-474
29. Wong Y.N., Mitra N., Hudes G., et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 296 (2006) 2683-2693
30. Holmberg L., Bill-Axelson A., Garmo H., et al. Prognostic markers under watchful waiting and radical prostatectomy. Hematol Oncol Clin North Am 20 (2006) 845-855